Therapeutic Solutions International, Inc. (OTC Pink: TSOI) is engaged within the research, development, and testing of immune modulation-based treatments for a variety of diseases. Shares of the medical developer surged 60% during trading on Tuesday, May 15, 2018. Over the past month, Therapeutic Solutions International, Inc. has seen average daily volume of 597,422 shares. However, volume of 6.7 million shares or dollar volume of $53,600, exchanged hands during trading on Tuesday.
Shares of Therapeutic Solutions International, Inc. soared today after the company announced that it has received an Institutional Review Board (IRB) clearance to begin the clinical trial of its cancer immunotherapy treatment, NanoStilbene. The trial testing will focus on the nanoparticle-delivered pterostilbene treatment’s ability to treat cancer. Here is the full press release detailing of the upcoming clinical trial:
Therapeutics Solutions International, Inc. Press Release:
OCEANSIDE, Calif., May 15, 2018 (GLOBE NEWSWIRE) — Via OTC PR Wire –Therapeutics Solutions International, Inc., (OTC Markets:TSOI) announced today Institutional Review Board (IRB) clearance to initiate a pilot pharmacokinetic trial of its nanoparticle delivered pterostilbene product called “NanoStilbene.”
Pterostilbene has been demonstrated in numerous publications, summarized at www.projuvenol.com/lit to possess therapeutic effects in animal models of numerous inflammatory-associated conditions including cancer, diabetes, and heart failure. One of the limitations of clinically developing pterostilbene is delivering enough of the product to the cells that need it, the Company hopes to overcome this by the use of nanoparticles.
“The initiation of a formal clinical trial evaluating the efficacy of the nanoparticles in NanoStilbene is a major milestone in the development of our product. Only through solid science can we be positioned to state exactly the advantages of the nano-formulation technology utilized in the manufacture of NanoStilbene,” said Timothy Dixon, President, and CEO of Therapeutic Solutions International.
The Company currently holds an issued US Patent on increasing efficacy of cancer immunotherapies using pterostilbene and nanoformulations including those utilized in the manufacture of NanoStilbene.
“Clinical trials are a fundamental part of developing any therapeutic agent. I am excited to be working with the Company on performing clinical trials on a nutraceutical, which demonstrates to me the commitment Therapeutic Solutions International has to develop superior nutraceuticals that can be integrated into standard medical practice,” said Dr. James Veltmeyer, member of the Company’s Advisory Board and Medical Monitor of the clinical study.
About Therapeutic Solutions International, Inc.: Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. The Company’s corporate website is www.therapeuticsolutionsint.com.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
